Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Touches CN¥22b Market Cap

Key Insights Insiders appear to have a vested interest in Nanjing King-Friend Biochemical PharmaceuticalLtd's growth, as seen by their sizeable ownership The top 3 shareholders own 68% of the compan

Simply Wall StMay 6 08:58

Jianyou Co., Ltd. (603707) Annual Report Review Report: Formulation exports maintained high growth under pressure due to impairment and low API prices

Jianyou Co., Ltd. released its 2023 annual report. The company achieved operating income of 3,931 billion yuan in 2023, an increase of 5.89%; net profit to mother - 189 million yuan, a year-on-year decrease of 117.37%; net profit not attributable to mother

國盛證券May 2 00:00

NKFPharma Gets Nod to Register New Cancer Treatment

Jianjin Pharmaceutical, a unit of Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707), received the drug registration certificate from China's National Medical Products Administration for bort

MT NewswiresMay 1 14:32

Express News | Jianyou Co., Ltd.: The subsidiary obtained the registration certificate for injectable bortezomib from the State Drug Administration

BreakingsApr 30 17:04

Jianyou Co., Ltd. (603707): Overall performance continues to be fulfilled under short-term pressure, overseas pharmaceutical exports continue to be fulfilled

Event: On April 26, 2024, the company released the 2023 annual report and the first quarter report of 2024. In 2023, the company achieved operating revenue of 3,931 billion yuan, an increase of 5.89% over the previous year.

銀河證券Apr 29 00:00

Express News | Nanjing Jianyou and Livingzhu Group collaborated to export injectable cetrorelix acetate to the US for the first time

BreakingsApr 28 11:45